Department of General and Pancreatic Surgery, Verona Hospital Trust, University of Verona, P.le A. Scuro 10, 37134, Verona, Italy.
Updates Surg. 2021 Apr;73(2):379-390. doi: 10.1007/s13304-021-00996-7. Epub 2021 Feb 13.
Pancreatoduodenectomy (PD) associated with colonic resections (CR) (PD-CR) might be a viable option in case of locally advanced periampullary tumors or right colon cancer. The aim of this review was to reappraise the indications and outcomes of PD-CR focusing on the occurrence of postoperative pancreatic fistula (POPF) and colonic anastomotic leak (CAL). A systematic literature search was performed in Medline and Cochrane Central Register of Controlled Trials (CENTRAL) for studies published between 2000 and 2020 concerning PD-CR for periampullary or colonic neoplasms. Twenty-seven studies were selected. Morbidity after PD-CR ranged from 12 to 65% and surgery-related mortality was approximately 10%. When reported, the rates of POPF and AL were as high as 40% and 33%, respectively. The oncological results were strictly linked to the nature of the primary tumor and did not significantly differ from those achieved with standard resections. Surgical radicality and nodal status resulted the main determinants of outcome for pancreatic and colonic cancer, respectively. Solid evidence about the surgical outcomes of PD-CR is lacking, mainly due to the small proportion of patients undergoing such combined resection. Given the elevated surgical risk, a multidisciplinary evaluation is recommended for patient's selection. The increasing use of neoadjuvant therapies is expected to further change the indications and outcomes of PD-CR in the next future.
胰十二指肠切除术(PD)联合结肠切除术(CR)(PD-CR)可能是局部晚期壶腹周围肿瘤或右半结肠癌的可行选择。本综述旨在重新评估 PD-CR 的适应证和结果,重点关注术后胰瘘(POPF)和结肠吻合口漏(CAL)的发生。对 2000 年至 2020 年间发表的有关胰头十二指肠或结肠肿瘤行 PD-CR 的研究,在 Medline 和 Cochrane 中央对照试验注册库(CENTRAL)中进行了系统文献检索。共选择了 27 项研究。PD-CR 后的发病率从 12%到 65%不等,与手术相关的死亡率约为 10%。当报告时,POPF 和 AL 的发生率分别高达 40%和 33%。肿瘤学结果与原发肿瘤的性质密切相关,与标准切除术的结果无显著差异。手术的根治性和淋巴结状态是胰腺癌和结肠癌的主要预后决定因素。PD-CR 手术结果的可靠证据不足,主要是因为接受这种联合切除术的患者比例较小。鉴于手术风险较高,建议进行多学科评估以选择患者。新辅助治疗的使用增加预计将在未来进一步改变 PD-CR 的适应证和结果。